BFRI
Biofrontera Inc.
BFRI lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
BFRI Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Under pressure | |
| Unavailable |
BFRI's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
BFRI PE Valuation
BFRI has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 3.7x next year's earnings.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
BFRI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
BFRI has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
BFRI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.25 | — |
| Q3 2024 | -$1.33 | +$18.59 |
| Q2 2024 | -$4.99 | +$12.40 |
| Q1 2024 | -$12.17 | -$1.06 |
| Q4 2023 | -$14.89 | -2541% |
BFRI has the stronger earnings trend. Trailing diluted EPS is down 109% for BFRI versus HIMS down 257%.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
BFRI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $12M | +33% |
| Q1 2026 | $10.1M | +17% |
| Q4 2025 | $17.1M | +36% |
| Q3 2025 | $7M | -22% |
| Q2 2025 | $9M | +15% |
| Q1 2025 | $8.6M | +8.5% |
| Q4 2024 | $12.6M | +19% |
| Q3 2024 | $9M | +1.3% |
BFRI's revenue is growing: $12M last quarter, up 33% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -4.4% | +52 points |
| Q1 2026 | -43% | +10 points |
| Q4 2025 | 27% | +40 points |
| Q3 2025 | -90% | -35 points |
| Q2 2025 | -56% | +8.4 points |
| Q1 2025 | -53% | +16 points |
| Q4 2024 | -14% | +23 points |
| Q3 2024 | -55% | -3.1 points |
BFRI has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over BFRI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
BFRI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$1.7M | +$1.4M |
| Q1 2026 | -$75K | +$4M |
| Q4 2025 | -$2.4M | -$1.4M |
| Q3 2025 | -$3.8M | -$2.6M |
| Q2 2025 | -$3M | +$1.6M |
| Q1 2025 | -$4.1M | -$738K |
| Q4 2024 | -$1M | +$7.8M |
| Q3 2024 | -$1.2M | +$796K |
BFRI has burned cash in almost every quarter: −$8M over the past year, against −$9M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over BFRI on cash generation, producing positive trailing cash flow while its opponent burns cash.
BFRI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +11% | +1.2M shares |
| 1 year | +38% | +3.6M shares |
| 3 years | +868% | +11.6M shares |
| 5 years | +2128% | +12.3M shares |
BFRI has 13M diluted shares, up 38% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over BFRI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
BFRI Net Leverage
BFRI's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
BFRI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.2 | Neutral |
| Stochastic | 10.9 | Oversold |
BFRI's weekly RSI is 44 (neutral) and its Stochastic is 11 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
BFRI PE vs Healthcare Sector
BFRI has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
BFRI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.92 | 1.1% above |
| 20 week MA | $1.15 | 19% below |
| 50 week MA | $1.00 | 7% below |
| 100 week MA | $0.95 | 2.1% below |
| 200 week MA | $3.17 | 71% below |
BFRI has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
BFRI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $88.2 | $263.4 | +198% |
| 2022 | $263.4 | $18.6 | -93% |
| 2023 | $18.6 | $2.77 | -85% |
| 2024 | $2.77 | $1.11 | -60% |
| 2025 | $1.11 | $0.72 | -35% |
| 2026 YTD | $0.72 | $0.93 | +29% |
BFRI has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.